ERBB2 and ductal breast carcinoma in situ: We also observed a low frequency of HER-2 expression in invasive disease as compared to the DCIS cases, confirming previous reports.22–26 Like that of HER-2, Fra-1 expression may be characteristic of tumours at a discrete stage of pathogenesis.